rdf:type |
|
lifeskim:mentions |
umls-concept:C0020792,
umls-concept:C0055944,
umls-concept:C0205314,
umls-concept:C0220908,
umls-concept:C0243077,
umls-concept:C0279516,
umls-concept:C0439208,
umls-concept:C0441655,
umls-concept:C0521009,
umls-concept:C0599740,
umls-concept:C0679622,
umls-concept:C1446409,
umls-concept:C1527178,
umls-concept:C1705938,
umls-concept:C1708373
|
pubmed:issue |
14
|
pubmed:dateCreated |
1999-2-4
|
pubmed:abstractText |
This SAR study has shown that the salicylanilide is the pharmacophore for inhibition of the bacterial two-component system. Hydrophobic substituents improve the potency of inhibitors in this series; however, hydrophobicity is not the sole determinant for inhibition; structural and electronic requirements also exist. Closantel (1) was found to inhibit a two-component system and to have antibacterial activity against drug resistant S. aureus and E. faecium.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0960-894X
|
pubmed:author |
pubmed-author:BarrettJ FJF,
pubmed-author:DemersJ PJP,
pubmed-author:FolenoB DBD,
pubmed-author:Fraga-SpanoS ASA,
pubmed-author:GuanJJ,
pubmed-author:HilliardJ JJJ,
pubmed-author:HlastaD JDJ,
pubmed-author:MacielagM JMJ,
pubmed-author:OhemengK AKA,
pubmed-author:SheppardC MCM,
pubmed-author:SurMM,
pubmed-author:WebbG CGC,
pubmed-author:Weidner-WellsM AMA,
pubmed-author:WerbloodHH
|
pubmed:issnType |
Print
|
pubmed:day |
21
|
pubmed:volume |
8
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1923-8
|
pubmed:dateRevised |
2003-11-14
|
pubmed:meshHeading |
|
pubmed:year |
1998
|
pubmed:articleTitle |
Novel inhibitors of bacterial two-component systems with gram positive antibacterial activity: pharmacophore identification based on the screening hit closantel.
|
pubmed:affiliation |
R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ 08869, USA.
|
pubmed:publicationType |
Journal Article
|